Veru Inc. is trading 11.5% up at $3.29, continuing a period of high volatility following a major company announcement earlier in the week.
- On June 4, Veru announced a clinical supply agreement with Novo Nordisk to evaluate its drug enobosarm in a Phase 2b obesity trial.
- The news caused the stock to surge over 88% on June 4, and it has experienced significant price swings since.
- The current upward move is part of the ongoing market reaction and heightened investor interest following this significant partnership.